Loading…
Gland Pharma (GLAND)₹3,302+5.41%Pharmaceuticals
At the end of the Jun 2026 quarter, Gland Pharma's shareholders were: promoters 51.73%, FIIs 8.75%, DIIs 30.47%, public 9.05%. Promoter holding is down 0.06 percentage points from 51.79% a quarter earlier. FII holding is up 1.35 percentage points from 7.40% a year earlier. 0.00% of promoter shares were pledged. It had 1,08,224 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 57.82% | 57.82% | 57.82% | 51.79% | 51.79% | 51.79% | 51.79% | 51.79% | 51.79% | 51.79% | 51.79% | 51.73% |
| FIIs | 4.92% | 4.06% | 3.60% | 6.89% | 4.49% | 5.05% | 6.91% | 7.40% | 7.91% | 7.59% | 7.30% | 8.75% |
| DIIs | 22.48% | 24.20% | 25.26% | 32.86% | 35.40% | 34.83% | 33.30% | 32.89% | 32.66% | 33.02% | 33.39% | 30.47% |
| Public | 14.78% | 13.92% | 13.32% | 8.46% | 8.32% | 8.33% | 8.00% | 7.92% | 7.64% | 7.60% | 7.52% | 9.05% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 1,61,565 | 1,35,969 | 1,22,328 | 1,22,618 | 1,22,311 | 1,21,028 | 1,13,744 | 1,10,628 | 97,114 | 94,542 | 91,465 | 1,08,224 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Fosun Pharma Industrial Pte. Ltd | Promoter | 51.71% | −0.06 |
| Hdfc Mutual Fund - Hdfc Mid-Cap Fund | DII | 6.08% | −0.28 |
| Mirae Asset Large & Midcap Fund | DII | 5.64% | −1.23 |
| Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund | DII | 4.90% | −0.11 |
| Sbi Large & Midcap Fund | DII | 3.31% | +0.03 |
| Icici Prudential India Opportunities Fund | DII | 1.78% | −1.30 |
| Dsp Small Cap Fund | DII | 1.63% | −0.03 |
| Government Pension Fund Global | FII | 1.33% | −0.02 |
| Uti-Flexi Cap Fund | DII | 1.23% | 0.00 |
Promoters held 51.73% of Gland Pharma at the end of the Jun 2026 quarter, down 0.06 percentage points from 51.79% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 8.75% (up 1.45 percentage points from 7.30% a quarter earlier) and domestic institutions (DIIs) held 30.47% (down 2.92 percentage points from 33.39% a quarter earlier).
No. The Jun 2026 filing shows no pledged promoter shares.
Gland Pharma had 1,08,224 shareholders at the end of the Jun 2026 quarter, against 1,10,628 a year earlier.
Hdfc Mutual Fund - Hdfc Mid-Cap Fund (DII) held 6.08% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.